$JNJ RESULTS: Q4 🔸 ADJ EPS $2.04 vs. $2.29 y/y, EST $1.99 🔸 Sales $22.52B, +5.3% y/y, EST $22.43B 🔸 MedTech sales $8.19B, +6.7% y/y, EST $8.23B 🔸 Imbruvica revenue $731M, -7.2% y/y, EST $711.6M 🔸 Invega Sustenna revenue $1.06B, +5.1% y/y, EST $1.03B 🔸 Darzalex revenue $3.08B, +21% y/y, EST $3.02B 🔸 Erleada revenue $784M, EST $792.1M, 🔸 Tremfya revenue $949M, +4.3% y/y, EST $1.05B 🔸 Remicade revenue $359M, -16% y/y, EST $371.8M 🔸 Stelara revenue $2.35B, -15% y/y, EST $2.4B 🔸 Zytiga revenue $135M, -33% y/y, EST $134.4M 🔸 Xarelto revenue $676M, +29% y/y, EST $512.4M 🔸 Simponi rev. $583M, +16% y/y, EST $502.7M F/Y GUIDANCE 🔸 Sees sales $89.2B to $90B 🔸 Sees ADJ operating EPS $10.75 to $10.95 🔸 Sees ADJ EPS $10.50 to $10.70